Although subsequent CUPID‐2 studies did not meet the primary or any secondary endpoints, overexpression of SERCA2a via gene transfer continues to be a promising therapeutic strategy for the treatment of heart failure.68 It is to be noted that SUMOylation of SERCA2a was shown to be reduced along with low SUMO1 expression in the failing heart. This evidence concerns the gene SUMO1 and heart failure.